BIT M.Pharm FAQs
Ques. Is GPAT mandatory for M.Pharm (Pharmaceutics) admission at BIT Meerut?
Ans. GPAT score is required for admission through UPTAC counselling, which covers 85% of seats. However, 15% of seats are available under the management/direct quota, for which GPAT is not mandatory. Candidates without GPAT can apply directly through the institute's portal.
Ques. What is the total fee for M.Pharm (Pharmaceutics) at BIT Meerut?
Ans. The tuition fee is approximately Rs. 69,906 per year as per AFRC UP norms, making the total 2-year tuition fee around Rs. 1.40 Lakhs. Additional charges such as examination fees and development fees may apply. Hostel is optional and charged separately.
Ques. What is the difference between M.Pharm Pharmaceutics and M.Pharm Pharmacology at BIT Meerut?
Ans. M.Pharm Pharmaceutics focuses on drug formulation, drug delivery systems, and pharmaceutical technology, while M.Pharm Pharmacology focuses on the study of drug actions, mechanisms, and clinical pharmacology. Both are offered at BIT Meerut and lead to careers in different areas of the pharmaceutical industry.
Ques. What are the career prospects after M.Pharm (Pharmaceutics) from BIT Meerut?
Ans. Graduates can work in pharmaceutical R&D, formulation development, quality control, regulatory affairs, and clinical research organizations. They can also pursue Ph.D. programs or appear for government research positions (CSIR, ICMR, DRDO).
Ques. Can I get a GPAT fellowship during M.Pharm at BIT Meerut?
Ans. GPAT-qualified students may be eligible for a monthly stipend of Rs. 12,400 under the AICTE scheme, subject to the institute's recognition under the relevant AICTE program. Students should confirm this directly with BIT Meerut before admission.
Ques. What is the scope of Pharmaceutics specialization in the pharmaceutical industry?
Ans. Pharmaceutics is one of the most in-demand specializations in the pharmaceutical industry. Graduates with M.Pharm in Pharmaceutics are sought after by major pharma companies like Sun Pharma, Cipla, Dr. Reddy's, and Lupin for roles in formulation development, drug delivery research, and regulatory submissions.
Comments